Your browser doesn't support javascript.
loading
Menthacarin, a Proprietary Peppermint Oil and Caraway Oil Combination, Improves Multiple Complaints in Patients with Functional Gastrointestinal Disorders: A Systematic Review and Meta-Analysis.
Madisch, Ahmed; Frieling, Thomas; Zimmermann, Andrea; Hollenz, Margrit; Labenz, Joachim; Stracke, Berenike; Miehlke, Stephan.
Afiliación
  • Madisch A; Gastroenterology Center Bethanien, Frankfurt, Germany.
  • Frieling T; Internal Medicine/Clinic II, HELIOS-Kliniken, Krefeld, Germany.
  • Zimmermann A; Research & Development, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany.
  • Hollenz M; General Practitioner, Rödental, Germany.
  • Labenz J; Medical Department, Diakonie Klinikum Jung-Stilling, Siegen, Germany.
  • Stracke B; Research & Development, Dr. Willmar Schwabe GmbH & Co. KG, Karlsruhe, Germany, berenike.stracke@schwabe.de.
  • Miehlke S; Center for Digestive Diseases, Internal Medicine Center Eppendorf, Hamburg, Germany.
Dig Dis ; 41(3): 522-532, 2023.
Article en En | MEDLINE | ID: mdl-36502789
INTRODUCTION: This systematic review summarizes published data on Menthacarin, the proprietary combination of peppermint oil and caraway oil, in the treatment of functional gastrointestinal disorders. Efficacy was assessed by meta-analysis of placebo-controlled trials. METHODS: We searched PubMed, the Cochrane Library, and the manufacturer's information system for clinical studies investigating the safety and efficacy of Menthacarin. Efficacy analyses included change from baseline of epigastric pain and general improvement of the patients' condition. RESULTS: Five randomized trials involving 580 patients were found, demonstrating significant effects of Menthacarin on symptoms of functional dyspepsia (FD) compared to placebo or similar effects compared to a reference drug. Seven other studies reported favorable results on therapeutic application in FD patients with concomitant Helicobacter pylori infection, in irritable bowel syndrome (IBS), and on tolerability in FD patients from 12 years of age. Three trials in FD with 249 patients were eligible for meta-analysis. Results demonstrate a significant reduction in pain intensity (standardized mean difference: 0.80; 95% confidence interval (CI): 0.39-1.21) and in item 2 of the Clinical Global Impression Scale (risk ratio: 2.65; 95% CI: 1.81-3.87) for Menthacarin. CONCLUSIONS: Menthacarin was shown to be effective and safe for the treatment of FD and represents a promising option for symptoms of IBS.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Helicobacter pylori / Infecciones por Helicobacter / Síndrome del Colon Irritable / Dispepsia Tipo de estudio: Clinical_trials / Systematic_reviews Límite: Humans Idioma: En Revista: Dig Dis Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Helicobacter pylori / Infecciones por Helicobacter / Síndrome del Colon Irritable / Dispepsia Tipo de estudio: Clinical_trials / Systematic_reviews Límite: Humans Idioma: En Revista: Dig Dis Asunto de la revista: GASTROENTEROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza